ArticlePLOS digital health2025
Using machine learning and single nucleotide polymorphisms for improving rheumatoid arthritis risk Prediction in postmenopausal women.
Article in PLOS digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genetic factors contribute to 60-70% of the variability in rheumatoid arthritis (RA). However, few studies have used genetic variants to predict RA risk. This study aimed to enhance RA risk prediction by leveraging single nucleotide polymorphisms (SNPs) through machine-learning algorithms, utilizing Women's Health Initiative data. We developed four predictive models: 1) based on common RA risk factors, 2) model 1 incorporating polygenic risk scores (PRS) with principal components, 3) model 1 and SNPs after feature reduction, and 4) model 1 and SNPs with kernel principal component analysis. Each model was assessed using logistic regression (LR), random forest (RF), eXtreme Gradient Boosting (XGBoost), and support vector machine (SVM). Performance metrics included the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive and negative predictive values (PPV and NPV), and F1-score. The fourth model, integrating SNPs with XGBoost, outperformed all other models. In addition, the XGBoost model that combines genomic data with conventional phenotypic predictors significantly enhanced predictive accuracy, achieving the highest AUC of 0.90 and an F1 score of 0.83. The DeLong test confirmed significant differences in AUC between this model and the others (p-values < 0.0001), particularly highlighting its efficacy in utilizing complex genetic information. These findings emphasize the advantage of combining in-depth genomic data with advanced machine learning for RA risk prediction. The most robust performance of the XGBoost model, which integrated both conventional risk factors and individual SNPs, demonstrates its potential as a tool in personalized medicine for complex diseases like RA. This approach offers a more nuanced and effective RA risk assessment strategy, underscoring the need for further studies to extend broader applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.